ResoTher Pharma is excited to announce that the company has won a Phase I SME grant under the European Union Horizon2020 funding scheme. The grant will support the preparations for clinical development of RTP-026, a novel peptide drug for resolution of inflammation.
For more information about the Horizon2020 funding scheme see here: https://ec.europa.eu/programmes/horizon2020/en